Stockscreener 앱 받기
23.31
2.34%
0.66
Pacira Biosciences Inc 주식(PCRX)의 최신 뉴스
2026-03-24 | Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira faces board fight as activist investor criticizes CEO pay, missed earnings - MSN
(PCRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Insider Sell: Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX) - GuruFocus
Froimson Mark sells Pacira BioSciences (PCRX) shares for $10905 By Investing.com - Investing.com South Africa
Insider Selling: Pacira BioSciences (NASDAQ:PCRX) Insider Sells 3,261 Shares of Stock - MarketBeat
Froimson Mark sells Pacira BioSciences (PCRX) shares for $10905 - Investing.com UK
Pacira BioSciences’ chief medical officer sells $74k in stock By Investing.com - Investing.com Canada
Pacira BioSciences (PCRX) director receives 6,163 restricted stock units in equity grant - Stock Titan
Pacira BioSciences (NASDAQ: PCRX) CMO sells 3,261 company shares - Stock Titan
Pacira BioSciences (PCRX) director sells 500 common shares in open market - Stock Titan
Pacira BioSciences unveils support hub for caregivers addressing chronic pain - Traders Union
Form 144 Pacira BioSciences For: 17 March By Investing.com - Investing.com Australia
[144] Pacira BioSciences, Inc. SE... | PCRX SEC FilingForm 144 - Stock Titan
Pacira BioSciences (NASDAQ:PCRX) Shares Down 4.7%Time to Sell? - MarketBeat
PCRX (NASDAQ: PCRX) insider sale notice lists 3 share lots - Stock Titan
Profit Review: Will Pacira BioSciences Inc benefit from seasonality2026 Big Picture & Weekly High Return Stock Opportunities - baoquankhu1.vn
Radcliffe Capital Management L.P. Takes $1.23 Million Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences advances non opioid pain therapies to transform patient care - Traders Union
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation - Sahm
Activist DOMA takes 7.3% Pacira (NASDAQ: PCRX) stake and targets CEO, board - Stock Titan
Pacira BioSciences responds to DOMA director nominations - Investing.com Australia
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc. - Morningstar
[DFAN14A] Pacira BioSciences, Inc. SEC Filing - Stock Titan
Activist hedge fund pushes Pacira BioSciences to sell itself - The Business Journals
Pacira Faces Board Fight As Activist Investor Criticizes CEO Pay, Missed Earnings - Benzinga
Pacira BioSciences responds to DOMA director nominations By Investing.com - Investing.com India
DOMA nominates three for Pacira Biosciences (NASDAQ: PCRX), holds 7.1% - Stock Titan
Pacira BioSciences shares rise 2% as activist pushes for CEO removal - Investing.com Canada
Pacira BioSciences (NASDAQ:PCRX) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat
Liquidity Mapping Around (PCRX) Price Events - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Reach Out - ACCESS Newswire
Pacira BioSciences, Inc. $PCRX Shares Purchased by American Century Companies Inc. - MarketBeat
Earnings Beat: Does Pacira BioSciences Inc have consistent dividend growthQuarterly Profit Review & Accurate Entry/Exit Alerts - baoquankhu1.vn
Pacira (PCRX) Grants Inducement Awards to New Employees - GuruFocus
Pacira BioSciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) Presents a Compelling Value Investment Case - ChartMill
Vanguard Group Inc. Trims Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference - The Manila Times
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2025 Earnings Call Transcript - Insider Monkey
PCRX Earnings History & Surprises | EPS & Revenue Results | PACIRA BIOSCIENCES INC (NASDAQ:PCRX) - ChartMill
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences (NASDAQ:PCRX) Stock Price Up 4.6%What's Next? - MarketBeat
PCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR) - Bitget
Pacira BioSciences (PCRX) Shows Promising Results in Knee Surger - GuruFocus
Pacira BioSciences, Inc. Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
1.75%
1.57%
자본화:
|
볼륨(24시간):